youtube_live
Q3 2026 earnings • released • EPS beat +0.94% • Revenue beat +1.66%
See resultschevron_right
BSX:NYSE
Boston Scientific Corp
$42.62
arrow_upward
+0.41%(+0.17) 1D
Oct 29, 9:35:47 AM GMT-4 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BSX...
Open
$41.81
High
$43.02
Low
$41.81
Mkt. cap
61.56B
Avg. vol.
18.87M
Volume
82.03K
P/E ratio
17.98
52-wk high
$105.65
52-wk low
$39.57
EPS
$2.36
Beta
0.58
Shares outstanding
1.45B
No. of employees
59K
Open
$41.81
High
$43.02
Low
$41.81
Mkt. cap
61.56B
Avg. vol.
18.87M
Volume
82.03K
P/E ratio
17.98
52-wk high
$105.65
52-wk low
$39.57
EPS
$2.36
Beta
0.58
Shares outstanding
1.45B
No. of employees
59K
News stories
From web sources and news partners
GuruFocus
·
31 minutes ago
BSX Maintained by Baird -- Price Target Raised to $51.00
Yahoo Finance
·
32 minutes ago
Boston Scientific Corp (BSX) (Q3 2026) Earnings Call Highlights: Cyber Incident Slashes Growth ...
Trefis
·
1 hour ago
What Is Behind The Move In Boston Scientific Stock?
Benzinga
·
2 hours ago
These Analysts Revise Their Forecasts On Boston Scientific After Q3 Results
Profile
Boston Scientific Corporation is an American biotechnology and biomedical engineering firm and multinational manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
The company is known for developing the Taxus Stent, a drug-eluting stent that is used to open clogged arteries.
BSC is headquartered in Marlborough, Massachusetts and incorporated in Delaware. Wikipedia
About Boston Scientific Corp
CEOMichael F. Mahoney
Employees59K
FoundedJun 29, 1979
HeadquartersMarlborough, Massachusetts, United States
SectorMedical device
Websitebostonscientific.com
Analyst ratings
Based on 23 analysts giving stock ratings to BSX in the past 3 months
Buy
Buy
16
Hold
7
Sell
0
12-month forecast
Based on 23 Wall Street analysts offering 12 month price targets for BSX in the last 3 months.
Highest
Current $42.62
$60.00 (+40.76%)
Average
$51.55 (+20.94%)
Lowest
$44.00 (+3.23%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Patrick Wood UBS | Buy | Reiterated | $57.00 | +33.7% | 10/29/2026 |
Lee Hambright Bernstein | Buy | Maintained | $49.00 | +15% | 10/29/2026 |
Marie Thibault BTIG | Buy | Maintained | $49.00 | +15% | 10/28/2026 |
William Plovanic Canaccord Genuity | Buy | Maintained | $48.00 | +12.6% | 10/29/2026 |
Anthony Petrone Mizuho Securities | Buy | Maintained | $50.00 | +17.3% | 10/29/2026 |
Kendall Au RBC Capital | Buy | Reiterated | $52.00 | +22% | 10/28/2026 |
Joanne Wuensch Citi | Hold | Reiterated | $44.00 | +3.2% | 10/29/2026 |
Suraj Kalia Oppenheimer | Hold | Downgraded | - | - | 10/29/2026 |
David Rescott Robert W. Baird | Buy | Maintained | $51.00 | +19.6% | 10/29/2026 |
Mike Kratky Leerink Partners | Buy | Reiterated | $50.00 | +17.3% | 10/29/2026 |
Christopher Pasquale Barclays | Hold | Maintained | $48.00 | +12.6% | 10/29/2026 |
Matthew Taylor Jefferies | Hold | Downgraded | $46.00 | +7.9% | 10/28/2026 |
Robbie Marcus J.P. Morgan | Hold | Downgraded | - | - | 10/28/2026 |
Michael Matson Needham | Buy | Maintained | $48.00 | +12.6% | 10/28/2026 |
Rick Wise Stifel Nicolaus | Buy | Maintained | $55.00 | +29% | 10/26/2026 |
Richard Newitter Truist Financial | Buy | Maintained | $51.00 | +19.6% | 10/14/2026 |
Matthew O'Brien Piper Sandler | Buy | Maintained | $60.00 | +40.8% | 10/14/2026 |
Matt Miksic Barclays | Hold | Maintained | $48.00 | +12.6% | 10/07/2026 |
Unknown Analyst Bernstein | Buy | Reiterated | $54.00 | +26.7% | 10/02/2026 |
Larry Biegelsen Wells Fargo | Hold | Reiterated | $48.00 | +12.6% | 09/24/2026 |
Travis Steed Bank of America Securities | Buy | Maintained | $54.00 | +26.7% | 09/20/2026 |
Josh Jennings TD Cowen | Buy | Maintained | $56.00 | +31.4% | 09/17/2026 |
David Toung Argus Research | Hold | Downgraded | - | - | 07/30/2026 |
Vijay Kumar Evercore ISI | Buy | Maintained | $55.00 | +29% | 07/30/2026 |
Pito Chickering Deutsche Bank | Buy | Maintained | $60.00 | +40.8% | 07/30/2026 |
Shagun Singh Chadha RBC Capital | Buy | Reiterated | $70.00 | +64.2% | 07/29/2026 |
Unknown Analyst Oppenheimer | Buy | Maintained | $85.00 | +99.4% | 07/27/2026 |
David Roman Goldman Sachs | Buy | Maintained | $57.00 | +33.7% | 07/14/2026 |
Stephanie Elghazi Bank of America Securities | Buy | Maintained | $68.00 | +59.5% | 06/09/2026 |
Michael Polark Wolfe Research | Hold | Downgraded | - | - | 05/29/2026 |
Hans Engel Erste Group | Hold | Reiterated | - | - | 04/01/2026 |
Jayson Bedford Raymond James | Buy | Maintained | $88.00 | +106.5% | 03/27/2026 |
Danielle Antalffy UBS | Buy | Reiterated | $105.00 | +146.3% | 03/17/2026 |
Last report
Oct 28, 2026
Fiscal period
Q3 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
$0.73 / $0.72
+0.94%beat
arrow_upward
Revenue / Est. (USD)
5.14B / 5.05B
+1.66%beat
arrow_upward
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 5.06B | 5.29B | 5.20B | 5.44B |
Cost of goods sold | 1.54B | 1.61B | 1.60B | 1.61B |
Cost of revenue | 1.54B | 1.61B | 1.60B | 1.61B |
Research and development expenses | 514.00M | 569.00M | 516.00M | 554.00M |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 1.74B | 1.83B | 1.78B | 1.80B |
Operating expense | 2.48B | 2.63B | 2.53B | 2.59B |
Total operating expenses | 4.02B | 4.24B | 4.13B | 4.20B |
Operating income | 1.05B | 1.04B | 1.07B | 1.25B |
Other non operating income | -16.00M | 28.00M | 28.00M | -6.00M |
EBT including unusual items | 938.00M | 700.00M | 1.16B | 1.06B |
EBT excluding unusual items | 935.00M | 1.01B | 999.00M | 1.14B |
Income tax expense | 183.00M | 30.00M | -176.00M | 155.00M |
Effective tax rate | 19.51% | 4.29% | -15.13% | 14.62% |
Other operating expenses | - | - | - | - |
Net income | 755.00M | 672.00M | 1.34B | 907.00M |
Net profit margin | 14.91% | 12.71% | 25.77% | 16.67% |
Earnings per share | 0.75 | 0.80 | 0.80 | 0.86 |
Interest and investment income | - | 29.00M | - | 11.00M |
Interest expense | -87.00M | -90.00M | -90.00M | -96.00M |
Net interest expenses | -87.00M | -61.00M | -90.00M | -85.00M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | 1.39B | 1.41B | 1.42B | 1.60B |
Gain or loss from assets sale | - | - | - | - |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1
Upcoming events